Skip to Content


In the US, Palonosetron (palonosetron systemic) is a member of the drug class 5HT3 receptor antagonists and is used to treat Nausea/Vomiting - Chemotherapy Induced and Nausea/Vomiting - Postoperative.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antiemetic agent

Serotonin 5HT₃-receptor antagonist

Chemical Names

(3aS)-2,3,3a,4,5,6-hexahydro-2-[(3S)-3-quinuclidinyl]-1H-benz[de]isoquinolin-1-one (WHO)

(3aS)-2,3,3a,4,5,6-Hexahydro-2-[(S)-chinuclidin-3-yl]-1H-benzo[de]isochinolin-1-on (IUPAC)

(3aS)-2,3,3a,4,5,6-tetrahidro-2-[(3S)-3-quinuclidinil]-1H-benz[de]isoquinolin-1-ona (WHO)

(3aS)-2-[(3S)-1-azabicyclo[2,2,2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolein-1-one (WHO)

1H-Benz(de)isoquinolin-1-one SB: 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro- ST: (S-(R*, R*))-

1H-Benz(de)isoquinolin-1-one SB: 2-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro- ST: (3aS)- (9CI)

Foreign Names

  • Palonosetronum (Latin)
  • Palonosetron (German)
  • Palonosétron (French)
  • Palonosetrón (Spanish)

Generic Names

Brand Names

  • Aloxi
    Helsinn, Slovakia; Helsinn Birex, Cyprus; Mundipharma, Malaysia; Mundipharma, Singapore; Pierre Fabre, Taiwan
  • Emegrand
    Grand Pharma, Egypt
  • Onicit
    MSD, Peru; Schering-Plough, Ecuador
  • Palnox
    Glenmark, India
  • Paloron
    Ziska, Bangladesh
  • Paloxi
    Kalbe, Indonesia
  • Paloxiron
    Incepta, Bangladesh
  • Palzen
    Dr. Reddy's, India
  • Akynzeo (Palonosetron and Netupitant)
    Chugai Pharma UK, United Kingdom; Helsinn Healthcare, United States; Riemser Pharma, Germany; Vifor, Switzerland
  • Aloxi
    Chugai Pharma UK, United Kingdom; CJ Cheiljedang, South Korea; Eisai, United States; Helsinn, Czech Republic; Helsinn, Greece; Helsinn, Italy; Helsinn, Lithuania; Helsinn, Norway; Helsinn, Poland; Helsinn, Romania; Helsinn, Thailand; Helsinn Birex, Latvia; Helsinn Birex Pharmaceuticals, Austria; Helsinn Birex Pharmaceuticals, Estonia; Helsinn Birex Pharmaceuticals Ltd, Serbia; Helsinn Healthcare, Hong Kong; Helsinn Healthcare, Vietnam; Helsinn Producso Farmacêuticos, SA, Portugal; Italfarmaco, Spain; Mundipharma, Philippines; Onko-Koçsel, Turkey; PharmaSwiss, Croatia (Hrvatska); PharmaSwiss, Serbia; Riemser Pharma, Germany; SOBI, Sweden; Specialised Therapeutics, Australia; Swedish Orphan, Denmark; Swedish Orphan Biovitrum, Finland; Taiho Yakuhin, Japan; Vifor, Belgium; Vifor, Switzerland; Vifor France, France
  • Jiouting
    Jiuyuan Gene Engineering, China
  • Lowvo
    Simcere, China
  • Onicit
    Merck Sharp & Dohme, Chile; MSD, Costa Rica; MSD, Dominican Republic; MSD, Guatemala; MSD, Honduras; MSD, Nicaragua; MSD, Panama; MSD, El Salvador; Pfizer, South Africa; Schering-Plough, Mexico
  • Onicit-Ponv
    Merck Sharp & Dohme, Chile
  • Palodin
    Koçak, Turkey
  • Palonosetron Teva
    Teva, Israel
  • Paloxi
    Helsinn Healthcare, Israel
  • Viqet
    Accord Farma, Mexico
  • Votron
    Biem, Turkey
  • Zhiruo
    Chia Tai Tianqing, China


IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.